

Accepted Manuscript

Temporal Trends in Initiation of Therapy With Tumor Necrosis Factor Antagonists for Patients With Inflammatory Bowel Disease: A Population-based Analysis

Laura E. Targownik, Aruni Tenakaroon, Stella Leung, Lisa M. Lix, Harminder Singh, Charles N. Bernstein



PII: S1542-3565(17)30195-7
DOI: [10.1016/j.cgh.2017.01.035](https://doi.org/10.1016/j.cgh.2017.01.035)
Reference: YJCGH 55117

To appear in: *Clinical Gastroenterology and Hepatology*
Accepted Date: 31 January 2017

Please cite this article as: Targownik LE, Tenakaroon A, Leung S, Lix LM, Singh H, Bernstein CN, Temporal Trends in Initiation of Therapy With Tumor Necrosis Factor Antagonists for Patients With Inflammatory Bowel Disease: A Population-based Analysis, *Clinical Gastroenterology and Hepatology* (2017), doi: 10.1016/j.cgh.2017.01.035.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Title: Temporal Trends in Initiation of Therapy With Tumor Necrosis Factor Antagonists for Patients With Inflammatory Bowel Disease: A Population-based Analysis

Short Title: Trends in Anti-TNF Initiation

Authors: Laura E, Targownik^{1,3}, Aruni Tenakaroon², Stella Leung, Lisa M. Lix^{2,3}, Harminder Singh^{1,3}, Charles N. Bernstein^{1,3}

Affiliations:

¹Department of Internal Medicine, University of Manitoba, Winnipeg, Manitoba, Canada

²Department of Community Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.

³University of Manitoba IBD Clinical and Research Centre

Grant Support: Supported by Crohn's and Colitis Canada Grants in Aid of Research

Abbreviations:

TNF – tumor necrosis factor

IBD – inflammatory bowel disease

CD – Crohn's Disease

UC – Ulcerative Colitis

IM - Immunomodulators

Send Correspondence to:

Laura Targownik, MD, MSHS

805G-715 McDermot Avenue

Winnipeg, Manitoba

R3E 3P4

email: laura.targownik@med.umanitoba.ca

Word Count: 3545 (manuscript), 623 (references)

Competing Disclosures:

Laura Targownik: Speaker's Panel for Janssen Canada, Takeda Canada, Pfizer Canada. Grant Support from Pfizer Canada and Abbvie Canada. Advisory Boards for Takeda Canada, Abbvie Canada, Janssen Canada.

Charles Bernstein: Advisory Boards for Abbvie Canada, Janssen Canada, Shire Canada, Takeda Canada, Pfizer, Cubist Pharmaceuticals. Educational grants from Abbvie Canada, Shire Canada, Takeda Canada, Janssen Canada. Speaker's panel for Abbvie Canada and Shire Canada

Harminder Singh: Advisory board Pendopharm; Grant support:Merck Canada

All other authors: No competing interests

Download English Version:

<https://daneshyari.com/en/article/5657200>

Download Persian Version:

<https://daneshyari.com/article/5657200>

[Daneshyari.com](https://daneshyari.com)